DAFNA Capital Management LLC Buys 19,000 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

DAFNA Capital Management LLC boosted its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,208 shares of the medical device company's stock after purchasing an additional 19,000 shares during the period. Tandem Diabetes Care comprises about 2.0% of DAFNA Capital Management LLC's holdings, making the stock its 16th largest holding. DAFNA Capital Management LLC owned about 0.34% of Tandem Diabetes Care worth $8,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Hood River Capital Management LLC acquired a new stake in Tandem Diabetes Care in the fourth quarter valued at approximately $46,035,000. Brown Advisory Inc. bought a new position in shares of Tandem Diabetes Care in the fourth quarter worth $32,889,000. Park West Asset Management LLC grew its stake in Tandem Diabetes Care by 49.5% in the 4th quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock worth $57,632,000 after buying an additional 530,000 shares in the last quarter. Baillie Gifford & Co. lifted its stake in Tandem Diabetes Care by 235.7% in the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after purchasing an additional 523,843 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after purchasing an additional 337,026 shares during the last quarter.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction on Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.90% of the company's stock.

Tandem Diabetes Care Stock Up 4.4 %

TNDM stock opened at $22.26 on Thursday. The stock has a market capitalization of $1.48 billion, a PE ratio of -11.53 and a beta of 1.47. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm has a 50 day moving average of $18.55 and a 200 day moving average of $28.34. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period in the previous year, the firm posted ($0.65) earnings per share. The company's revenue was up 22.3% compared to the same quarter last year. Sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on TNDM. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $35.00 to $24.00 in a research note on Tuesday, March 4th. Mizuho began coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Piper Sandler decreased their price target on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $39.81.

Read Our Latest Stock Report on Tandem Diabetes Care

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Featured Articles

• Five stocks we like better than Tandem Diabetes Care
• Why Understanding Call Option Volume is Essential to Successful Options Trading
• DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
• What Does Downgrade Mean in Investing?
• Uber’s Earnings Offer Clues on the Stock and Broader Economy
• Do ETFs Pay Dividends? What You Need to Know
• Institutions Skipped the Rally: Where the Money Went

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tandem Diabetes Care Right Now?

Before you consider Tandem Diabetes Care, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.

While Tandem Diabetes Care currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here